Related references
Note: Only part of the references are listed.Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary
Tomoyuki Sasano et al.
MOLECULAR CANCER RESEARCH (2015)
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors
Maria Elena Elez et al.
CLINICAL CANCER RESEARCH (2014)
Combination Treatment With Trabectedin and Irinotecan or Topotecan Has Synergistic Effects Against Ovarian Clear Cell Carcinoma Cells
Mahiru Kawano et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)
Michela Romano et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Potential Role of mTORC2 as a Therapeutic Target in Clear Cell Carcinoma of the Ovary
Takeshi Hisamatsu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
August Vidal et al.
CLINICAL CANCER RESEARCH (2012)
The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2011)
Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
Daniele G. Soares et al.
MOLECULAR CANCER THERAPEUTICS (2011)
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity
J. F. M. Leal et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Mucinous But Not Clear Cell Histology Is Associated With Inferior Survival in Patients With Advanced Stage Ovarian Carcinoma Treated With Platinum-Paclitaxel Chemotherapy
Aristotle Bamias et al.
CANCER (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2009)
MOLECULAR ORIGINS OF CANCER DNA Damage, Aging, and Cancer
Jan H. J. Hoeijmakers
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data
Julian R. Molina et al.
CLINICAL CANCER RESEARCH (2008)
Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
William E. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary
David R. Crotzer et al.
GYNECOLOGIC ONCOLOGY (2007)
Trabectedin- A review of its use in the management of soft tissue sarcoma and ovarian cancer
Natalie J. Carter et al.
DRUGS (2007)
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary
H Itamochi et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
Y Takebayashi et al.
NATURE MEDICINE (2001)
Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors
A Taamma et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
